Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Recommendation of “Moderate Buy” from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $41.00.

A number of equities research analysts have recently commented on the company. Mizuho set a $40.00 price target on Assembly Biosciences and gave the stock an “outperform” rating in a research report on Thursday, November 20th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, December 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st.

Assembly Biosciences Stock Performance

ASMB opened at $26.37 on Tuesday. The firm’s fifty day moving average is $32.31 and its two-hundred day moving average is $28.27. The firm has a market cap of $417.17 million, a PE ratio of -5.51 and a beta of 1.13. Assembly Biosciences has a twelve month low of $7.75 and a twelve month high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). The firm had revenue of $10.79 million during the quarter, compared to the consensus estimate of $7.46 million. Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%. Equities analysts forecast that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASMB. Bank of America Corp DE increased its holdings in Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Assembly Biosciences during the third quarter worth about $282,000. ADAR1 Capital Management LLC acquired a new stake in Assembly Biosciences in the 3rd quarter valued at approximately $485,000. Millennium Management LLC acquired a new stake in Assembly Biosciences in the 3rd quarter valued at approximately $553,000. Finally, Acadian Asset Management LLC lifted its stake in Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 6,823 shares in the last quarter. 19.92% of the stock is owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.